Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
Menta “Steve” Wallace shows a bottle of daraxonrasib, Revolution Medicines’ pancreatic cancer drug, at his home in The…
Lil Nas X’s bipolar diagnosis and mental health treatment| STAT
When Lil Nas X recently disclosed that he had been diagnosed with bipolar disorder, one part of his…
Enveda weight loss maintenance pill mimics exercise in early tests
If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…
Lilly sues six firms over alleged illegal sales of obesity drug retatrutide
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Foundayo: Eli Lilly wins U.K. approval, challenging Wegovy weight-loss pill
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
FedEx is chasing the GLP-1 boom. Why healthcare logistics means big business
The boom in GLP-1 weight-loss drugs and other specialized medicines has created lucrative logistics opportunities in an industry…
Novo Nordisk shares fall after heart medicine trial results
Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart…
Novo Nordisk looks to block Eli Lilly weight-loss drug ads
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters Novo Nordisk said on…